Despite adequately documented evidence of the effectiveness of the antimalarials quinacrine and chloroquine in the treatment of discoid lupus erythematosus,* a significant number of patients receiving these drugs derive little or no benefit from them, either because of side-effects of sufficient severity to compel discontinuance of medication, or simply because of lack of therapeutic effect. The desirability of a drug with greater therapeutic response, better tolerance, and less toxicity was evident, so when preliminary laboratory studies with Plaquenil \s=d\ revealed such advantageous properties in malaria, clinical evaluation of this drug in the treatment of discoid lupus erythematosus seemed logical.
[1]
R. Preston,et al.
Chloroquine diphosphate in treatment of discoid lupus erythematosus.
,
1953,
Journal of the American Medical Association.
[2]
G. M. Lewis,et al.
Atabrine in the treatment of discoid lupus erythematosus.
,
1952,
The Journal of investigative dermatology.
[3]
G. Wells.
Treatment of chronic discoid lupus erythematosus with atabrine.
,
1952,
The Journal of investigative dermatology.
[4]
H. F. Hammer,et al.
The Preparation of 7-Chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1- methylbutylamino)-quinoline and Related Compounds
,
1950
.